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Access to some C5-cyclised 2-pyrones and 2-pyridones via direct 
arylation; retention of chloride as a synthetic handle 
Aisling M. Prendergast,[a] Leticia M. Pardo,[a] Ian J. S. Fairlamb[b] and Gerard P. McGlacken*[a] 
Abstract: The synthetic effort towards the functionalisation of C±H 
bonds on 2-pyrones and 2-pyridones has been funnelled by the 
preferential reactivity of the C-3 position. Herein, we report a direct 
arylation protocol for the intramolecular coupling of 2-pyrones and 
2-pyridones, allowing access to a previously unavailable class of C-5 
cyclised products with an unstudied biological profile. A C±Cl bond 
was retained at C-3 during the direct arylation process allowing further 
derivatisation at C-3, which we have demonstrated with a Suzuki-
Miyaura cross-coupling reaction. 
Introduction 
Effective routes to aryl-heteroaryl (Ar-HetAr) bonds are 
among the most important in organic synthesis[1] due to the 
abundance of the Ar-HetAr moiety in natural products and 
pharmaceuticals.[2] The development of direct arylation protocols 
involving at least one C±H activation event is highly sought after 
by academic[3] and industrial groups.[4] 
We chose to focus on the 2-pyrone substrate, specifically 4-
hydroxy-2-pyrone[5] derivatives due to their status as a privileged 
scaffold with broad spectrum biological activity,[6] spanning 
cytotoxic,[5] antibiotic,[6] and antifungal activity.[7] 2-Pyridones 
(isosteres of 2-pyrones) possess numerous biological effects 
including antifungal, antibacterial, insecticidal and cytotoxic 
activity.[8] The 2-pyrone moiety also displays chemical reactivity 
reminiscent of aromatics,[9] dienes[10] and enones,[11] and thus 
represents a highly challenging, yet rewarding, synthon. 
Moreover, it has been demonstrated to ring-open under certain 
cross-coupling conditions.[12] 
In terms of functionalisation at the free C-3 and C-5 positions, 
the inherent reactivity of the C-3 position on the 2-pyrone scaffold 
has completely funnelled the synthetic effort (Scheme 1). More 
specifically, direct arylation at the C-3 position has been well-
studied by us[13] and others.[14] What has been almost completely 
untapped, is the biological profile of similar compounds, 
functionalised at C-5 position (Scheme 1), presumably because 
of the lack of selective synthetic methods. 
 
Scheme 1. Untapped 2-pyrone framework cyclised at C-5. 
Previously, we reported that the use of a methyl group (1a) or 
a bromo group (1b) at the C-3 position could facilitate access to 
the C-5 coupled products (Scheme 2).[13a] 
 
Scheme 2. Comparison to previous work, which was limited to a non-functional 
C-3 blocking group. 
While the transformation of 1a to 2a proceeded in good yield, 
the methyl group cannot be easily manipulated. We reasoned that 
by using bromide (1b), the direct arylation at C-5±H could be 
achieved, provided oxidative addition was preferred at the aryl 
iodide and that no complications were encountered due to the Br 
at C-3. While direct arylation was accomplished, prohibitive 
hydrodebromination dominated (giving 2b).  
Using the direct arylation/hydrodebromination protocol, we set 
about elaboration of the substrate scope. Unfortunately, all 
attempts were met with failure. For example, an analogue bearing 
a phenyl ring at C-6 failed to give any product. Neither did the 2-
pyridone isostere, under otherwise identical reaction conditions. 
Even if this strategy had proved successful, gaining access to 5-
cyclised compounds bearing a halogen at C-3 for further 
elaboration, would have to occur via a 
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hydrodehalogenation/rehalogenation protocol, which is clearly 
neither atom- nor step-economic. 
Instead, we sought to develop a Pd-catalysed direct arylation 
protocol which would (1) give direct arylation at C-5, (2) be 
generally applicable and (3) allow further decoration of the 2-
pyrone motif at C-3. As Lautens observed,[15] there is a notable 
absence of polyhalogenated substrates in Pd-catalysed cross-
couplings, which is probably due to selectivity issues. This 
potential pitfall was offset by the potential for follow-on coupling 
using an (hetero)aryl chloride, the benefits of which have been 
well documented by Buchwald,[16] Hartwig[17] and Fu.[18] 
Results and Discussion 
In our study, using a chloride as the blocking group in pyrone 
1c proved successful (Scheme 2). As expected, complications 
arose when employing other combinations of halides (X = Br and 
I, possessing weaker C±X bonds) on the aryl ring and on the C-3 
position (see SI). 
 An optimisation screen was performed using 1c as starting 
material. Employing Cs2CO3 as the base in THF under Jeffery-
type conditions[19] gave the desired product 2c in 55% yield (Table 
1, entry 1). Changing to K2CO3 gave a slight improvement in yield 
to 60% (Table 1, entry 2). This is in line with our previous 
observation that Cs2CO3 can degrade the 2-pyrone motif.[13b] 
Employing KOAc as the base in toluene gave a 68% yield (Table 
1, entry 3) and it was determined to be the optimal base. 
Switching to a protic polar solvent system inhibited the reaction 
(Table 1, entry 4), but using an aprotic polar solvent gave a 95% 
yield in just 4 hours (Table 1, entry 5). In THF the reactions worked 
very well (85%, isolated yield) and it was chosen over DMF[20] as 
our reaction solvent (Table 1, entry 6). With our optimised 
conditions in hand, we next investigated the substrate scope. To 
this end, a variety of 2-pyrone and 2-pyridone precursors were 
prepared. 
Table 1. Optimisation of direct arylation conditions (1cĺ2c). 
 
 Solvent Base T (°C) Time (h) Product (%)[a] 
1 THF Cs2CO3 76 8 55 
2 THF K2CO3 76 8 60 
3 Toluene KOAc 110 6 68 
4 EtOH/H2O KOAc 100 16 0 
5 DMF KOAc 100 4 95 
6 THF KOAc 76 18 85 
[a] Isolated yields, following chromatography on silica gel. 
Pleasingly, a number of substrates were well tolerated under 
the reaction conditions (Scheme 3). Substituents para to the 
oxidative addition site worked well, with a p-methyl substituted 
aryl halide giving product 10 in 53% yield, a p-methoxy substituted 
aryl halide giving 11 in 63% yield and a p-fluoro substituted aryl 
halide giving 12 in 43% yield.  
 Importantly, and in contrast to our previous studies,[13a] the 
2-pyridone substrates also coupled well, giving the desired 
products 13 and 14 in moderate yields.  
Unfortunately, employing a larger substituent at the 6-position 
failed to give any product 9, presumably due to unfavourable 
steric interactions at Pd. In any case, the 6-Me 2-pyrone is the 
more common and useful synthon due to its biosynthetic pathway 
(from acetyl-CoA via two sequential condensations with malonyl-
CoA and subsequent ring closure to produce triacetic acid lactone, 
also called 4-hydroxy-6-methyl-2-pyrone).[21] 
 
Scheme 3. Substrate scope, showcasing the viability of the C-5 direct arylation 
protocol. 
Having demonstrated the scope of the direct arylation reaction, 
we turned our attention towards further functionalisation of the 2-
pyrone product via Suzuki-Miyaura cross-coupling at the C-3±Cl 
position of 2c. To this end, we expected to be able to harness the 
plethora of conditions reported for the Suzuki-Miyaura cross-
coupling of aryl chlorides. Disappointingly, conditions such as 
those reported by Fu (Table 2, entry 1)[18c] and Buchwald (Table 
2, entry 2)[16a] for the cross-coupling of aryl chlorides failed to give 
the desired product 15. 
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Table 2. Optimisation of Suzuki-Miyaura cross-coupling. 
 
 Pd Ligand Base Solvent T 
(°C) 
Conv. 
(%)[a] 
1[b] Pd2(dba)3 P(tBu)3.HBF4 KF THF 60 0 
2[c] Pd(OAc)2 DavePhos CsF Dioxane 110 0 
3 Pd(OAc)2 SPhos[d] K2CO3 Toluene 110 60 
4 Pd(OAc)2 SPhos[d] KOAc Toluene 110 70 
5 Pd(OAc)2 SPhos KOAc 2-MeTHF 90 69 
6 Pd(OAc)2 SPhos KOAc Dioxane 110 44 
7 Pd2(dba)3 SPhos KOAc THF 76 6 
8 Pd(OAc)2 XPhos KOAc THF 76 29 
9 Pd(OAc)2 RuPhos KOAc THF 76 64 
10 Pd(OAc)2 SPhos KOAc THF 76 93 (92) 
[a] Conversion calculated from 1H NMR spectrum of crude reaction mixture. 
Isolated yields in parenthesis. [b] Pd2(dba)3 (1.5 mol%), P(tBu)3.HBF4 (3.6 
mol%) and KF (3.3 equiv.). [c] Pd(OAc)2 (2 mol%), DavePhos (3 mol%) and 
CsF (3.0 equiv.). [d] 10 mol%. 
However, upon consideration of the 13C NMR spectrum of 2c, 
it became apparent that the C-3±Cl bond (13C at 100.8 ppm) did 
not necessarily possess the characteristics of an aryl chloride 
bond. We therefore tested the conditions reported by Hultin for 
the Suzuki-Miyaura cross-coupling of an Į-chloro-Įȕ-
unsaturated ester (Table 2, entry 3).[22] To our delight, similar 
conditions gave 60% conversion to the desired product 15.[23] 
Using KOAc as base (Table 2, entry 4), gave a slightly increased 
conversion (to 70%). Using 2-MeTHF (Table 2, entry 5) and 1,4-
dioxane (Table 2, entry 6) as solvents, did not promote the 
reaction. Changing to a Pd(0) source in THF surprisingly led to 
poor catalytic turnover (6% conversion, Table 2, entry 7), and 
using bulkier phosphine ligands (Table 2, entries 8-9) was also 
relatively unsuccessful. Finally, using KOAc in refluxing THF 
(Table 2, entry 10) gave 93% conversion and an excellent isolated 
yield of 92%.[24]  
 Use of an electron-poor p-(CF3)phenylboronic acid gave the 
appropriate product 16 in 57% (isolated yield) however, electron-
rich p-(OMe)phenylboronic acid gave only 28% conversion to 17 
(Scheme 4). 
 
Scheme 4. Substrate scope for the Suzuki-Miyaura cross-coupling reaction. 
Conclusions 
We have developed a valuable synthetic methodology 
allowing access to previously inaccessible, C-5-cyclised, 
2-pyrones and 2-pyridones. This protocol proceeds via direct 
arylation with the retention of a C±Cl bond; the latter can be 
utilised in a Suzuki-Miyaura cross-coupling, enabling further 
elaboration at C-3. 
Experimental Section 
1. General Information: THF was distilled from sodium in the presence of 
benzophenone. Pd(OAc)2 was recrystallised from toluene. All other 
reagents and solvents were used as purchased unless otherwise stated. 
Melting points were measured in a Thomas Hoover Capillary Melting Point 
apparatus and are reported uncorrected. Infrared (IR) spectra were 
recorded on a Perkin-Elmer FT-IR Paragon 1000 spectrophotometer. 
Liquid samples were examined as thin films interspersed between sodium 
chloride plates. Solid samples were dissolved in dichloromethane (DCM), 
applied as a thin film to sodium chloride plates and the DCM allowed to 
evaporate prior to the recording of spectra. Mass spectra were recorded 
on a Waters LCT Premier Tof LC-MS instrument in electrospray ionisation 
mode using 50% acetonitrile-water, containing 0.1% formic acid, as eluent; 
samples were made up in acetonitrile or methanol. All spectra were 
recorded at University College Cork. NMR spectra were run in 
deuteriochloroform (CDCl3) using tetramethylsilane (TMS) as the internal 
standard, unless otherwise specified. NMR spectra were recorded on a 
Bruker AVANCE 300 instrument at University College Cork. Thin layer 
chromatography was performed on precoated silica gel (Merck HF254) 
plates and compounds were visualised under U.V. light. Column 
chromatography was carried out using Fluka silica gel 60. 
2. Experimental Procedures 
2.1 General Procedure for Preparation of 4-benzyloxy-2-pyrones: 
Pyrone (1.0 equiv.), 2-iodobenzylbromide (1.2 equiv.), K2CO3 (3.0 equiv.) 
and acetone (4 mL/mmol pyrone) were added to a round-bottomed flask. 
The flask was placed in an oil bath preheated to 79 °C and the reaction 
was stirred at this temperature for 4 h, then cooled to ambient temperature. 
The reaction mixture was diluted with 15 mL water and extracted with 3 × 
15 mL EtOAc. The combined organic layers were washed with 20 mL 
water, dried over MgSO4 and concentrated under reduced pressure. The 
residues were purified by column chromatography using the indicated 
eluent to afford the products. 
4-((2-iodobenzyl)oxy)-6-methyl-2H-pyran-2-one[13a] 0.5:99.5 
MeOH:DCM; White solid (1.022 g, 33%); m.p. (DCM) 105±106 °C (lit.[13a] 
101-103 °C); 1H NMR (300 MHz, CDCl3įGJ = 7.8, 1H), 7.39 (d, J 
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= 4.2, 2H), 7.15 ± 6.99 (m, 1H), 5.87 (dd, J = 2.0, 0.9, 1H), 5.51 (d, J = 2.2, 
1H), 5.01 (s, 2H), 2.23 (s, 3H); 13C NMR (75 MHz, CDCl3į (qC), 
164.8 (qC), 162.4 (qC), 139.7 (CH), 136.8 (qC), 130.3 (CH), 129.0 (CH), 
128.6 (CH), 100.3 (CH), 97.8 (qC), 88.8 (CH), 74.4 (CH2), 19.9 (CH3); m/z 
(ES+) 343 ((M+H)+ 100%). 
4-((2-Iodo-5-methylbenzyl)oxy)-6-methyl-2H-pyran-2-one DCM; White 
solid (0.236 g, 38%); m.p. (MeOH) 125±127 &,5Ȟmax 1719, 1649, 1566, 
1245, 1013, 806; 1H NMR (300 MHz, CDCl3įGJ = 8.0, 1H), 7.20 
(d, J = 1.6, 1H), 6.89 (dd, J = 8.0, 1.7, 1H), 5.88 (dd, J = 2.1, 0.9, 1H), 5.50 
(d, J = 2.1, 1H), 4.96 (s, 2H), 2.32 (s, 3H), 2.22 (s, 3H); 13C NMR (75 MHz, 
CDCl3į (qC), 164.8 (qC), 162.4 (qC), 139.4 (CH), 138.7 (qC), 136.4 
(qC), 131.3 (CH), 130.0 (CH), 100.4 (CH), 93.7 (qC), 88.7 (CH), 74.4 (CH2), 
21.0 (CH3), 19.9 (CH3); m/z (ES+) 357 ((M+H)+ 40%); HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C14H14IO3 356.9988; Found 356.9987. 
4-((2-Iodo-5-fluorobenzyl)oxy)-6-methyl-2H-pyran-2-one DCM; Pale 
yellow solid (0.143 g, 40%); m.p. (MeOH) 123±&,5Ȟmax 1714, 1650, 
1569, 1239, 1020, 666; 1H NMR (300 MHz, CDCl3įGGJ = 8.7, 5.5, 
1H), 7.15 (dd, J = 9.3, 3.0, 1H), 6.84 (td, J = 8.4, 3.0, 1H), 5.90 (dd, J = 
2.1, 0.9, 1H), 5.48 (d, J = 2.2, 1H), 4.96 (s, 2H), 2.24 (s, 3H); 13C NMR (75 
MHz, CDCl3įT&T&GJ = 249, qC), 162.7 (qC), 
140.7 (d, J = 8, CH), 139.0 (d, J = 7, qC), 117.5 (d, J = 22, CH), 115.9 (d, 
J = 24, CH), 100.2 (CH), 89.4 (d, J = 3, qC), 88.9 (CH), 73.7 (d, J = 1, CH2), 
19.9 (CH3); 19F NMR (282 MHz, CDCl3į -113; m/z (ES+) 361 ((M+H)+ 
6%); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H11IFO3 360.9737; Found 
360.9741. 
4-((2-Iodo-5-methoxybenzyl)oxy)-6-methyl-2H-pyran-2-one 0.5:99.5 
MeOH:DCM; Yellow solid (0.015 g, 4%, with the remainder (0.197 g) 
isolated as an inseparable mixture which was carried forward into the 
chlorination step); m.p. (MeOH) 100±& ,5Ȟmax 1727, 1651, 1566, 
1244, 1000, 811; 1H NMR (300 MHz, CDCl3įGJ = 8.7, 1H), 6.96 
(d, J = 3.0, 1H), 6.66 (dd, J = 8.7, 3.0, 1H), 5.88 (dd, J = 2.1, 0.9, 1H), 5.49 
(d, J = 2.1, 1H), 4.96 (s, 2H), 3.80 (s, 3H), 2.23 (s, 3H); 13C NMR (75 MHz, 
CDCl3į (qC), 164.7 (qC), 162.4 (qC), 160.2 (qC), 140.1 (CH), 137.7 
(qC), 115.8 (CH), 115.3 (CH), 100.3 (CH), 88.9 (CH), 85.6 (qC), 74.2 (CH2), 
55.5 (CH3), 19.9 (CH3); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H14IO4 
372.9937; Found 372.9949. 
4-((2-Iodobenzyl)oxy)-6-(4-methoxyphenyl)-2H-pyran-2-one DCM; 
Yellow solid (0.160 g, 67%); m.p. (MeOH) 107±&,5Ȟmax 1720, 1634, 
1510, 1178, 752; 1H NMR (300 MHz, CDCl3į± 7.78 (m, 1H), 7.74 ± 
7.62 (m, 2H), 7.41 ± 7.26 (m, 2H), 7.00 (ddd, J = 7.9, 6.9, 2.3, 1H), 6.93 ± 
6.83 (m, 2H), 6.34 (d, J = 2.1, 1H), 5.51 (d, J = 2.1, 1H), 4.98 (s, 2H), 3.78 
(s, 3H); 13C NMR (75 MHz, CDCl3įT&T&T&, 
160.6 (qC), 139.7 (CH), 136.9 (qC), 130.4 (CH), 129.1 (CH), 128.6 (CH), 
127.4 (2 x CH), 123.6 (qC), 114.3 (2 x CH), 97.8 (qC), 96.3 (CH), 89.0 
(CH), 74.5 (CH2), 55.5 (CH3);  m/z (ES±) 433 ((M±H)± 14%); HRMS (ESI-
TOF) m/z: [M+H]+ Calcd for C19H16IO4 435.0093; Found 435.0095. 
2.2 General Procedure for Preparation of 4-benzyloxy-2-pyridones A 
Schlenk tube was heated under vacuum and refilled with N2 three times. 
Pyridone (1.0 equiv.), 2-iodobenzylbromide (1.12 equiv.) and K2CO3 (3.0 
equiv.) were added under a flow of N2. Anhydrous DMF (4 mL/mmol 
pyridone) was added via syringe. The flask was placed in an oil bath 
preheated to 25 °C and the reaction was stirred at this temperature for 18 
h. The reaction mixture was diluted with 20 mL water and extracted with 3 
× 15 mL EtOAc. The combined organic layers were washed with 20 mL 
brine, dried over MgSO4 and concentrated under reduced pressure. The 
residues were purified by column chromatography to afford the pure 
products. 
4-((2-Iodobenzyl)oxy)-1,6-dimethylpyridin-2(1H)-one[13b] 50:50 
EtOAc:hexanes; White solid (0.112 g, 29%); m.p. (hexanes) 134±136 °C 
(lit.[13b] 134-136 °C),5Ȟmax 2906, 1644, 1591, 1566, 1435, 1356, 1236, 
1200; 1H NMR (300 MHz, CDCl3į± 7.72 (m, 1H), 7.54 ± 7.22 (m, 
2H), 6.02 ± 5.73 (m, 2H), 5.06 ± 4.77 (m, 2H), 3.65 ± 3.34 (m, 3H), 2.41 ± 
2.22 (m, 3H); 13C NMR (75 MHz, CDCl3įT&T&
(qC), 139.5 (CH), 137.8 (qC), 129.8 (CH), 128.7 (CH), 128.4 (CH), 100.8 
(CH), 97.5 (qC), 95.9 (CH), 73.7 (CH2), 30.6 (CH3), 20.9 (CH3); m/z (ES+) 
356 ((M+H)+ 16%); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H15INO2 
356.0148; Found 356.0144. 
4-((2-Iodobenzyl)oxy)-6-methyl-1-phenylpyridin-2(1H)-one 70:30 
EtOAc:hexanes; Yellow solid (0.805 g, 78%); m.p. (MeOH) 120±124 °C; 
,5Ȟmax 1662, 1590, 1558, 1354, 1241, 118, 1044, 755; 1H NMR (300 MHz, 
CDCl3įGGJ = 7.9, 0.8, 1H), 7.59 ± 7.32 (m, 5H), 7.24 ± 7.15 (m, 
2H), 7.05 (td, J = 7.7, 1.7, 1H), 5.98 (dd, J = 11.8, 2.2, 2H), 5.01 (s, 2H), 
1.92 (s, 3H); 13C NMR (75 MHz, CDCl3įT&T&
(qC), 139.5 (CH), 138.6 (qC), 137.8 (qC), 129.9 (CH), 129.7 (2 x CH), 
128.8 (CH), 128.7 (CH), 128.5 (CH), 128.3 (2 x CH), 100.8 (CH), 97.6 (qC), 
96.4 (CH), 73.9 (CH2), 21.5 (CH3); m/z (ES+) 418 ((M+H)+ 100%); HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C19H17INO2 418.0304; Found 418.0307. 
2.3 General Procedure for chlorination of 4-benzyloxy-2-pyrones and 
2-pyridones Pyrone or pyridone (1.0 equiv.) and N-chlorosuccinimide (1.2 
equiv.) were added to a round-bottomed flask. CHCl3 (5 mL/mmol pyrone 
or pyridone) was added, followed by trifluoroacetic acid (1.2 equiv.). The 
flask was covered in aluminium foil to exclude light and placed in an oil 
bath, which was heated to 55 °C. The reaction was stirred at this 
temperature until TLC analysis showed that all starting material had been 
consumed (18 ± 24 h). The reaction mixture was cooled to ambient 
temperature, diluted with 10 mL CHCl3 and washed with 15 mL saturated 
aqueous NaHCO3 and 2 × 15 mL water. The organic layer was dried over 
MgSO4 and concentrated under reduced pressure. The residues were 
purified by column chromatography using the indicated eluent to afford the 
pure products. 
3-Chloro-4-((2-iodobenzyl)oxy)-6-methyl-2H-pyran-2-one, 1c 0.5:99.5 
MeOH:DCM; White solid (0.742 g, 67%); m.p. (MeOH) 183±185 °C; IR 
Ȟmax 1725, 1640, 1543, 1322, 758; 1H NMR (300 MHz, CDCl3įGG
J = 7.9, 1.0, 1H), 7.45 (dtd, J = 8.8, 7.8, 1.4, 2H), 7.09 (td, J = 7.8, 1.9, 1H), 
6.06 (d, J = 0.7, 1H), 5.21 (s, 2H), 2.29 (d, J = 0.8, 3H); 13C NMR (75 MHz, 
CDCl3įT&T&T&&+T&
(CH), 128.9 (CH), 128.4 (CH), 100.5 (qC), 96.4 (qC), 96.1 (CH), 75.3 (CH2), 
20.3 (CH3); m/z (ES+) 377 (35Cl (M+H)+ 20%), 379 (37Cl (M+H)+ 8%); 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H11IClO3 376.9441; Found 
376.9446. 
3-Chloro-4-((2-iodobenzyl)oxy)-6-(4-methoxyphenyl)-2H-pyran-2-
one, 3 0.5:99.5 MeOH:DCM; Yellow solid (0.080 g, 49%); m.p. (MeOH) 
183±&,5Ȟmax 1713, 1625, 1507, 1265, 1180, 1107, 738; 1H NMR 
(300 MHz, CDCl3įGJ = 7.9, 1H), 7.81 ± 7.71 (m, 2H), 7.54 (d, J = 
7.7, 1H), 7.44 (t, J = 7.5, 1H), 7.09 (t, J = 7.6, 1H), 6.96 (d, J = 8.9, 2H), 
6.53 (s, 1H), 5.33 (s, 2H), 3.87 (d, J = 1.2, 3H); 13C NMR (75 MHz, CDCl3) 
įT&T&T&T&&+T&
130.4 (CH), 129.0 (CH), 128.6 (CH), 127.7 (2 x CH), 123.0 (qC), 114.5 (2 
x CH), 100.7 (qC), 96.6 (qC), 91.8 (CH), 75.3 (CH2), 55.5 (CH3); HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C19H15IClO3 468.9704; Found 468.9715. 
3-Chloro-4-((2-iodo-5-methylbenzyl)oxy)-6-methyl-2H-pyran-2-one, 4 
0.5:99.5 MeOH:DCM; White solid (0.164 g, 75%); m.p. (MeOH) 204±
206 °C; ,5Ȟmax 1722, 1638, 1544, 1319, 1239, 1075, 742; 1H NMR (300 
MHz, CDCl3įGJ = 8.0, 1H), 7.28 (d, J = 1.2, 1H), 6.91 (dd, J = 8.0, 
1.7, 1H), 6.06 (s, 1H), 5.17 (s, 2H), 2.34 (s, 3H), 2.29 (s, 3H); 13C NMR (75 
MHz, CDCl3įT&T& 160.8 (qC), 139.2 (CH), 139.1 (qC), 
136.4 (qC), 131.3 (CH), 129.3 (CH), 100.5 (qC), 96.2 (CH), 92.4 (qC), 75.3 
(CH2), 21.1 (CH3), 20.3 (CH3); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C14H13IClO3 390.9598; Found 390.9601. 
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3-Chloro-4-((2-iodo-5-methoxybenzyl)oxy)-6-methyl-2H-pyran-2-
one, 5 DCM; White solid (0.052 g, 24%); m.p. (DCM) 180±184 &,5Ȟmax 
1718, 1637, 1545, 1318, 1232, 1053, 873; 1H NMR (300 MHz, CDCl3į
7.71 (d, J = 8.7, 1H), 7.08 (d, J = 3.0, 1H), 6.67 (dd, J = 8.7, 3.0, 1H), 6.07 
(d, J = 0.6, 1H), 5.16 (s, 2H), 3.80 (s, 3H), 2.29 (d, J = 0.6, 3H); 13C NMR 
(75 MHz, CDCl3įT&T&T&T&
(CH), 137.7 (qC), 116.4 (CH), 114.2 (CH), 100.6 (qC), 96.1 (CH), 84.1 (qC), 
75.1 (CH2), 55.5 (CH3), 20.3 (CH3); HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C14H13IClO4 406.9547; Found 406.9550. 
3-Chloro-4-((2-iodo-5-fluorobenzyl)oxy)-6-methyl-2H-pyran-2-one, 6 
0.5:99.5 MeOH:DCM; White solid (0.036 g, 29%); m.p. (DCM) 221±223 °C; 
,5 Ȟmax 1719, 1639, 1544, 1321, 1235, 1074, 868; 1H NMR (300 MHz, 
CDCl3įGGJ = 8.7, 5.4, 1H), 7.37 ± 7.15 (m, 2H), 6.86 (td, J = 8.4, 
3.0, 1H), 6.05 (d, J = 0.6, 1H), 5.14 (s, 2H), 2.31 (d, J = 0.7, 3H); 13C NMR 
(75 MHz, CDCl3įT& (d, J = 249, qC), 161.7 (qC), 160.6 
(qC), 140.6 (d, J = 8, CH), 139.0 (d, J = 8, qC), 117.6 (d, J = 22, CH), 115.8 
(d, J = 24, CH), 100.8 (qC), 95.9 (CH), 88.3 (d, J = 3, qC), 74.6 (d, J = 1, 
CH2), 20.3 (CH3); 19F NMR (282 MHz, CDCl3į-112; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C13H10ClFIO3 394.9347; Found 394.9360. 
3-Chloro-4-((2-iodobenzyl)oxy)-1,6-dimethylpyridin-2(1H)-one, 7 
Recrystallised from EtOH; White solid (0.109 g, 50%); m.p. (EtOH) 170±
171 &,5Ȟmax 1659, 1635, 1600, 1019, 735; 1H NMR (300 MHz, CDCl3) 
įGGJ = 7.9, 1.1, 1H), 7.67 ± 7.49 (m, 1H), 7.40 (td, J = 7.6, 1.2, 1H), 
7.05 (ddd, J = 7.9, 7.4, 1.7, 1H), 5.96 (s, 1H), 5.14 (s, 2H), 3.56 (s, 3H), 
2.37 (d, J = 0.6, 3H); 13C NMR (75 MHz, CDCl3įT&T&
145.2 (qC), 139.2 (CH), 137.7 (qC), 129.9 (CH), 128.7 (CH), 128.3 (CH), 
106.4 (qC), 96.2 (qC), 95.9 (CH), 74.4 (CH2), 32.1 (CH3), 21.4 (CH3); 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H14IClNO2 389.9758; Found 
389.9761. 
3-Chloro-4-((2-iodobenzyl)oxy)-6-methyl-1-phenylpyridin-2(1H)-
one, 8 90:10 EtOAc:hexanes; Yellow solid (0.115 g, 15%); m.p. (MeOH) 
239±243 & ,5Ȟmax 1654, 1531, 1350, 1222, 1052, 751; 1H NMR (300 
MHz, CDCl3įGGJ = 7.9, 0.9, 1H), 7.60 (d, J = 7.7, 1H), 7.46 (m, 
4H), 7.22 ± 7.13 (m, 2H), 7.07 (td, J = 7.8, 1.6, 1H), 6.05 (s, 1H), 5.20 (s, 
2H), 1.98 (s, 3H); 13C NMR (75 MHz, CDCl3į (qC), 161.0 (qC), 
145.3 (qC), 139.3 (CH), 138.5 (qC), 137.7 (qC), 129.9 (CH), 129.8 (2 x 
CH), 129.0 (CH), 128.8 (CH), 128.4 (CH), 127.9 (2 x CH), 106.8 (qC), 96.2 
(qC), 95.9 (CH), 74.6 (CH2), 22.0 (CH3); m/z (ES+) 452 (35Cl (M+H)+ 100%), 
454 (37Cl (M+H)+ 38%); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C19H16IClNO2 451.9914; Found 451.9918. 
2.4 General Procedure for Direct Arylation A Schlenk tube was heated 
under vacuum and refilled with N2 three times. Pyrone or pyridone (1.0 
equiv.), Pd(OAc)2 (5 mol%), tetrabutylammonium bromide (TBAB) (1.2 
equiv.) and KOAc (2.5 equiv.) were added to the Schlenk tube under flow 
of N2. Freshly distilled THF (0.03 M) was added via syringe. The Schlenk 
was placed in an oil bath preheated to 76 °C and the reaction was stirred 
at this temperature for 18 h (pyrones) or 24 h (pyridones), then cooled to 
ambient temperature. The reaction mixture was diluted with 10 mL water 
and extracted with 3 × 10 mL DCM. The combined organic layers were 
dried over MgSO4 and concentrated under reduced pressure. The 
residues were purified by column chromatography using the indicated 
eluent to afford the pure products. 
 
4-Chloro-1-methyl-3H,6H-pyrano[4,3-c]isochromen-3-one, 2c DCM; 
White solid (0.028 g, 85%); m.p. (MeOH) 155±&,5Ȟmax 1726, 1638, 
1544, 1185, 770; 1H NMR (300 MHz, CDCl3į± 7.42 (m, 2H), 7.38 
(td, J = 7.3, 1.7, 1H), 7.27 (d, J = 7.4, 1H), 5.19 (s, 2H), 2.65 (s, 3H); 13C 
NMR (75 MHz, CDCl3į1 (qC), 159.9 (qC), 156.9 (qC), 131.0 (qC), 
129.1 (CH), 128.2 (CH), 125.7 (CH), 125.6 (qC), 125.4 (CH), 107.8 (qC), 
100.8 (qC), 70.2 (CH2), 20.3 (CH3); m/z (ES+) 249 (35Cl (M+H)+ 16%), 251 
(37Cl (M+H)+ 6%); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H10ClO3 
249.0318; Found 249.0318. Reaction performed with Pd(OAc)2 (2 mol%) 
and TBAB (1.0 equiv). 
4-Chloro-1,8-dimethyl-3H,6H-pyrano[4,3-c]isochromen-3-one, 10 
DCM; White solid (0.016 g, 53%); m.p. (DCM) 158±163 °C,5Ȟmax 1726, 
1634, 1548, 1301, 1190, 1033, 824; 1H NMR (300 MHz, CDCl3įG
J = 8.1, 1H), 7.25 (d, J = 8.4, 1H), 7.08 (s, 1H), 5.16 (s, 2H), 2.63 (s, 3H), 
2.40 (s, 3H); 13C NMR (75 MHz, CDCl3į (qC), 160.0 (qC), 156.2 
(qC), 138.4 (qC), 130.9 (qC), 129.8 (CH), 126.0 (CH), 125.6 (CH), 122.7 
(qC), 107.8 (qC), 100.8 (qC), 70.2 (CH2), 21.2 (CH3), 20.2 (CH3); m/z (ES+) 
263 (35Cl (M+H)+ 18%), 265 (37Cl (M+H)+ 6%); HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C14H12ClO3 263.0475; Found 263.0471. 
4-Chloro-8-methoxy-1-methyl-3H,6H-pyrano[4,3-c]isochromen-3-
one, 11 0.5:99.5 MeOH:DCM; White solid (0.013 g, 63%); m.p. (DCM) 
193±&,5Ȟmax 1728, 1635, 1544, 1502, 1140, 1052, 934; 1H NMR 
(300 MHz, CDCl3įGJ = 8.7, 1H), 6.98 (dd, J = 8.7, 2.7, 1H), 6.79 
(d, J = 2.6, 1H), 5.16 (s, 2H), 3.86 (s, 3H), 2.61 (s, 3H); 13C NMR (75 MHz, 
CDCl3įT&T&T&T&T&
(CH), 117.8 (qC), 114.7 (CH), 110.7 (CH), 107.6 (qC), 100.9 (qC), 70.2 
(CH2), 55.5 (CH3), 20.2 (CH3); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C14H12ClO4 279.0424; Found 279.0428. 
4-Chloro-8-fluoro-1-methyl-3H,6H-pyrano[4,3-c]isochromen-3-
one, 12 DCM; White solid (0.012 g, 43%); m.p. (DCM) 147±151 °C,5Ȟmax 
1733, 1635, 1549, 1495, 1185, 1027, 834; 1H NMR (300 MHz, CDCl3į
7.48 (dd, J = 8.8, 5.0, 1H), 7.17 (td, J = 8.6, 2.7, 1H), 7.01 (dd, J = 8.0, 2.6, 
1H), 5.17 (s, 2H), 2.63 (s, 3H); 13C NMR (75 MHz, CDCl3į162.6 (qC), 
162.0 (d, J = 251, qC), 159.7 (qC), 156.5 (d, J = 2, qC), 133.3 (d, J = 8, 
qC), 127.8 (d, J = 8, CH), 121.8 (d, J = 3, qC), 116.2 (d, J = 22, CH), 112.7 
(d, J = 23, CH), 107.2 (qC), 101.2 (qC), 69.6 (d, J = 2, CH2), 20.2 (CH3); 
19F NMR (282 MHz, CDCl3į-111.8; HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C13H9ClFO3 267.0224; Found 267.0229. 
4-Chloro-1,2-dimethyl-2,6-dihydro-3H-isochromeno[4,3-c]pyridin-3-
one, 13 0.3:99.7 MeOH:DCM; White solid (0.011 g, 55%); m.p. (DCM) 
218± & ,5Ȟmax 1730, 1651, 1533, 1266, 738; 1H NMR (300 MHz, 
CDCl3į± 7.14 (m, 4H), 5.06 (s, 2H), 3.70 (s, 3H), 2.73 (s, 3H); 13C 
NMR (75 MHz, CDCl3įT&T&T&T&
128.5 (CH), 128.5 (qC), 127.0 (CH), 126.3 (CH), 125.4 (CH), 107.9 (qC), 
106.1 (qC), 70.0 (CH2), 32.6 (CH3), 19.8 (CH3); m/z (ES+) 262 (35Cl (M+H)+ 
100%), 264 (37Cl (M+H)+ 38%);  HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C14H13NO2Cl 262.0635; Found 262.0639. 
4-Chloro-1-methyl-2-phenyl-2,6-dihydro-3H-isochromeno[4,3-
c]pyridin-3-one, 14 70:30 EtOAc:hexanes; Brown solid (0.018 g, 60%); 
PS'&0!&,5Ȟmax 1655, 1528, 1349, 1206, 1041, 700; 1H NMR 
0+]'062į± 7.50 (m, 4H), 7.48 ± 7.31 (m, 5H), 5.23 (s, 2H), 
2.27 (s, 3H); 13&1050+]'062įT&T&
(qC), 139.3 (qC), 132.5 (qC), 130.1 (CH), 129.3 (2 x CH), 128.9 (CH), 
128.9 (2 x CH), 128.3 (qC), 127.4 (CH), 126.8 (CH), 125.9 (CH), 107.1 
(qC), 104.9 (qC), 69.9 (CH2), 21.4 (CH3); HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C19H15NO2Cl 324.0791; Found 324.0787. 
2.5 General Procedure for Suzuki-Miyaura Cross-Coupling A Schlenk 
tube was heated under vacuum and refilled with N2 three times. KOAc (2.2 
equiv.) was added. The Schlenk tube was heated under vacuum and 
refilled with N2 twice. Pyrone or pyridone (1.0 equiv.), boronic acid (1.5 
equiv.), Pd(OAc)2 (5 mol%) and SPhos (15 mol%) were added. The 
Schlenk tube was evacuated and refilled with N2 three times. Freshly 
distilled THF (0.03 M) was added via syringe. The Schlenk tube was 
placed in an oil bath preheated to 76 °C. The reaction was stirred at this 
temperature for 18 h, then cooled to ambient temperature. The reaction 
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mixture was diluted with 15 mL water and extracted with 3 × 15 mL EtOAc. 
The combined organic layers were dried over MgSO4 and concentrated 
under reduced pressure. The residues were purified by column 
chromatography using the indicated eluent to afford the pure products. 
1-Methyl-4-(p-tolyl)-3H,6H-pyrano[4,3-c]isochromen-3-one, 15 DCM; 
White solid (0.034 g, 92%); m.p. (hexanes) 159±164 & ,5Ȟmax 1711, 
1555, 1161, 1013; 1H NMR (300 MHz, CDCl3įGJ = 7.7, 1H), 7.49 
± 7.29 (m, 4H), 7.22 (d, J = 8.3, 3H), 5.00 (s, 2H), 2.68 (s, 3H), 2.37 (s, 
3H); 13C NMR (75 MHz, CDCl3įT&, 163.4 (qC), 157.7 (qC), 137.6 
(qC), 131.7 (qC), 130.3 (2 x CH), 128.8 (CH), 128.7 (2 x CH), 128.0 (qC), 
127.6 (CH), 126.8 (qC), 125.9 (CH), 125.2 (CH), 107.9 (qC), 107.1 (qC), 
69.6 (CH2), 21.3 (CH3), 20.3 (CH3); m/z (ES+) 305 ((M+H)+ 100%); HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C20H17O3 305.1178; Found 305.1174. 
1-Methyl-4-(4-(trifluoromethyl)phenyl)-3H,6H-pyrano[4,3-
c]isochromen-3-one, 16 DCM; White solid (0.033 g, 57%); m.p. (DCM) 
188±&,5Ȟmax 1713, 1325, 1110, 845; 1H NMR (300 MHz, CDCl3į
7.65 (s, 4H), 7.54 (d, J = 7.6, 1H), 7.47 (td, J = 7.7, 1.2, 1H), 7.37 (td, J = 
7.4, 1.2, 1H), 7.25 (d, J = 6.9, 1H), 5.03 (s, 2H), 2.70 (s, 3H); 13C NMR (75 
MHz, CDCl3į (qC), 162.8 (qC), 158.7 (qC), 134.9 (d, J = 1, qC), 
131.4 (qC), 130.9 (2 x CH), 129.5 (q, J = 32, qC), 129.0 (CH), 127.9 (CH), 
126.4 (qC), 125.9 (CH), 125.3 (CH), 124.8 (q, J = 4, 2 x CH), 124.2 (q, J = 
272, qC), 107.9 (qC), 105.7 (qC), 69.8 (CH2), 20.4 (CH3); 19F NMR (282 
MHz, CDCl3į-63; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C20H14F3O3 
359.0895; Found 359.0885. 
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